BIIB
Biogen Inc (BIIB)
Healthcare • NASDAQ • $216.78+1.13%
- Symbol
- BIIB
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Price
- $216.78
- Daily Change
- +1.13%
- Market Cap
- $31.00B
- Trailing P/E
- 37.34
- Forward P/E
- 12.64
- 52W High
- $219.72
- 52W Low
- $131.52
- Analyst Target
- $237.59
- Dividend Yield
- N/A
- Beta
- 0.16
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-as…
Company websiteResearch BIIB on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.